Selected research
Industry Research
Finished Dosage Form Antithrombin Industry Research Report 2026
Market perspective
The global Finished Dosage Form Antithrombin market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Finished Dosage Form Antithrombin market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Finished Dosage Form Antithrombin market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Finished Dosage Form Antithrombin market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Finished Dosage Form Antithrombin include Kedrion S.p.A., CSL Limited, Scripps Laboratories Inc., Lee Biosolutions, Grifols, LFB S.A./rEVO Biologics Inc. and Takeda, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Finished Dosage Form Antithrombin market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Finished Dosage Form Antithrombin.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Finished Dosage Form Antithrombin Market by Company
Kedrion S.p.A.
CSL Limited
Scripps Laboratories Inc.
Lee Biosolutions
Grifols
LFB S.A./rEVO Biologics Inc.
Takeda
Finished Dosage Form Antithrombin Segment by Type
Liquid
Lyophilized
Finished Dosage Form Antithrombin Segment by Application
Diagnostics
Therapeutics
Finished Dosage Form Antithrombin Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Finished Dosage Form Antithrombin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Finished Dosage Form Antithrombin and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Finished Dosage Form Antithrombin.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Finished Dosage Form Antithrombin companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Liquid
- Lyophilized
Applications
- Diagnostics
- Therapeutics
Companies covered
- Kedrion S.p.A.
- CSL Limited
- Scripps Laboratories Inc.
- Lee Biosolutions
- Grifols
- LFB S.A./rEVO Biologics Inc.
- Takeda
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Finished Dosage Form Antithrombin by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Liquid
- 2.2.3 Lyophilized
- 2.3 Finished Dosage Form Antithrombin by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Diagnostics
- 2.3.3 Therapeutics
- 2.4 Assumptions and Limitations
3 Finished Dosage Form Antithrombin Breakdown Data by Type
- 3.1 Global Finished Dosage Form Antithrombin Historic Market Size by Type (2021-2026)
- 3.2 Global Finished Dosage Form Antithrombin Forecasted Market Size by Type (2027-2032)
4 Finished Dosage Form Antithrombin Breakdown Data by Application
- 4.1 Global Finished Dosage Form Antithrombin Historic Market Size by Application (2021-2026)
- 4.2 Global Finished Dosage Form Antithrombin Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Finished Dosage Form Antithrombin Market Perspective (2021-2032)
- 5.2 Global Finished Dosage Form Antithrombin Growth Trends by Region
- 5.2.1 Global Finished Dosage Form Antithrombin Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Finished Dosage Form Antithrombin Historic Market Size by Region (2021-2026)
- 5.2.3 Finished Dosage Form Antithrombin Forecasted Market Size by Region (2027-2032)
- 5.3 Finished Dosage Form Antithrombin Market Dynamics
- 5.3.1 Finished Dosage Form Antithrombin Industry Trends
- 5.3.2 Finished Dosage Form Antithrombin Market Drivers
- 5.3.3 Finished Dosage Form Antithrombin Market Challenges
- 5.3.4 Finished Dosage Form Antithrombin Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Finished Dosage Form Antithrombin Players by Revenue
- 6.1.1 Global Top Finished Dosage Form Antithrombin Players by Revenue (2021-2026)
- 6.1.2 Global Finished Dosage Form Antithrombin Revenue Market Share by Players (2021-2026)
- 6.2 Global Finished Dosage Form Antithrombin Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Finished Dosage Form Antithrombin Head Office and Area Served
- 6.4 Global Finished Dosage Form Antithrombin Players, Product Type & Application
- 6.5 Global Finished Dosage Form Antithrombin Manufacturers Established Date
- 6.6 Global Finished Dosage Form Antithrombin Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Finished Dosage Form Antithrombin Market Size (2021-2032)
- 7.2 North America Finished Dosage Form Antithrombin Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Finished Dosage Form Antithrombin Market Size by Country (2021-2026)
- 7.4 North America Finished Dosage Form Antithrombin Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Finished Dosage Form Antithrombin Market Size (2021-2032)
- 8.2 Europe Finished Dosage Form Antithrombin Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Finished Dosage Form Antithrombin Market Size by Country (2021-2026)
- 8.4 Europe Finished Dosage Form Antithrombin Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Finished Dosage Form Antithrombin Market Size (2021-2032)
- 9.2 Asia-Pacific Finished Dosage Form Antithrombin Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Finished Dosage Form Antithrombin Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Finished Dosage Form Antithrombin Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Finished Dosage Form Antithrombin Market Size (2021-2032)
- 10.2 South America Finished Dosage Form Antithrombin Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Finished Dosage Form Antithrombin Market Size by Country (2021-2026)
- 10.4 South America Finished Dosage Form Antithrombin Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Finished Dosage Form Antithrombin Market Size (2021-2032)
- 11.2 Middle East & Africa Finished Dosage Form Antithrombin Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Finished Dosage Form Antithrombin Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Finished Dosage Form Antithrombin Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Kedrion S.p.A.
- 12.1.1 Kedrion S.p.A. Company Information
- 12.1.2 Kedrion S.p.A. Business Overview
- 12.1.3 Kedrion S.p.A. Revenue in Finished Dosage Form Antithrombin Business (2021-2026)
- 12.1.4 Kedrion S.p.A. Finished Dosage Form Antithrombin Product Portfolio
- 12.1.5 Kedrion S.p.A. Recent Developments
- 12.2 CSL Limited
- 12.2.1 CSL Limited Company Information
- 12.2.2 CSL Limited Business Overview
- 12.2.3 CSL Limited Revenue in Finished Dosage Form Antithrombin Business (2021-2026)
- 12.2.4 CSL Limited Finished Dosage Form Antithrombin Product Portfolio
- 12.2.5 CSL Limited Recent Developments
- 12.3 Scripps Laboratories Inc.
- 12.3.1 Scripps Laboratories Inc. Company Information
- 12.3.2 Scripps Laboratories Inc. Business Overview
- 12.3.3 Scripps Laboratories Inc. Revenue in Finished Dosage Form Antithrombin Business (2021-2026)
- 12.3.4 Scripps Laboratories Inc. Finished Dosage Form Antithrombin Product Portfolio
- 12.3.5 Scripps Laboratories Inc. Recent Developments
- 12.4 Lee Biosolutions
- 12.4.1 Lee Biosolutions Company Information
- 12.4.2 Lee Biosolutions Business Overview
- 12.4.3 Lee Biosolutions Revenue in Finished Dosage Form Antithrombin Business (2021-2026)
- 12.4.4 Lee Biosolutions Finished Dosage Form Antithrombin Product Portfolio
- 12.4.5 Lee Biosolutions Recent Developments
- 12.5 Grifols
- 12.5.1 Grifols Company Information
- 12.5.2 Grifols Business Overview
- 12.5.3 Grifols Revenue in Finished Dosage Form Antithrombin Business (2021-2026)
- 12.5.4 Grifols Finished Dosage Form Antithrombin Product Portfolio
- 12.5.5 Grifols Recent Developments
- 12.6 LFB S.A./rEVO Biologics Inc.
- 12.6.1 LFB S.A./rEVO Biologics Inc. Company Information
- 12.6.2 LFB S.A./rEVO Biologics Inc. Business Overview
- 12.6.3 LFB S.A./rEVO Biologics Inc. Revenue in Finished Dosage Form Antithrombin Business (2021-2026)
- 12.6.4 LFB S.A./rEVO Biologics Inc. Finished Dosage Form Antithrombin Product Portfolio
- 12.6.5 LFB S.A./rEVO Biologics Inc. Recent Developments
- 12.7 Takeda
- 12.7.1 Takeda Company Information
- 12.7.2 Takeda Business Overview
- 12.7.3 Takeda Revenue in Finished Dosage Form Antithrombin Business (2021-2026)
- 12.7.4 Takeda Finished Dosage Form Antithrombin Product Portfolio
- 12.7.5 Takeda Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst